Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges.

Current opinion in pulmonary medicine - 1 Nov 2021

Barry Peter J, Taylor-Cousar Jennifer L

Abstract excerpt

PURPOSE OF REVIEW: The purpose of this review is to describe on-going and upcoming real-world studies that will aid the cystic fibrosis (CF) community in understanding the long-term efficacy, safety and challenges in utilizing this therapy and managing care. RECENT FINDINGS: The triple combination of elexacaftor, tezacaftor and ivacaftor (ETI) has been demonstrated to improve lung function, weight and quality of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Child
Share to Cystic Fibrosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Drug Combinations

Share to Mutation

Share to Quality of Life

Source

Identifiers

PMID: 34420018
DOI: 10.1097/MCP.0000000000000819

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges.PMID 34420018Read ↗

Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor.Semantic proximity Read ↗

Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis.Semantic proximity Read ↗

Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy.Semantic proximity Read ↗

Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation.Semantic proximity Read ↗

The New and Advanced Cystic fibrosis transmembrane conductance regulators Modulators in Children with Cystic Fibrosis: A Narrative Review on Long-Term Outcomes, Recent Advances, and Comparative Insights.Semantic proximity Read ↗

Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update.Semantic proximity Read ↗

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.Semantic proximity Read ↗

Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy.Semantic proximity Read ↗

Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype.Semantic proximity Read ↗

Precision Medicine Based on CFTR Genotype for People with Cystic FibrosisSemantic proximity Read ↗

Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?Semantic proximity Read ↗

Tezacaftor for the treatment of cystic fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.